Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory...

Area of Science:

• Endocrinology
• Genetics
• Pediatric Medicine

Background:

• Pediatric hypoparathyroidism typically stems from genetic mutations affecting parathyroid development or calcium signaling.
• Rare cases involve autoimmune destruction of parathyroid glands, often linked to autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
• Conventional treatment with calcium and vitamin D analogs is generally effective but poses management challenges in specific conditions like APECED or with calcium-sensing receptor mutations.

Observation:

• Three pediatric patients diagnosed with hypoparathyroidism were treated.
• Continuous subcutaneous administration of recombinant human parathyroid hormone (rhPTH(1-34)) was employed.
• Two of the treated patients had conditions refractory to conventional therapies.

Findings:

• Continuous subcutaneous rhPTH(1-34) administration proved successful in treating all three pediatric patients.
• This therapeutic approach was particularly effective for patients whose hypoparathyroidism was resistant to standard calcium and vitamin D treatments.
• The study highlights a viable alternative treatment for complex pediatric hypoparathyroidism cases.

Implications:

• Continuous rhPTH(1-34) offers a promising alternative for managing difficult-to-treat pediatric hypoparathyroidism.
• This treatment strategy may improve outcomes for children with genetic or autoimmune forms of the condition.
• Further research into rhPTH(1-34) for pediatric endocrine disorders is warranted.